Evogene Q2 net loss narrows to USD 1.8 million; revenue slips to USD 0.3 million - EVGN News | RalliesEvogene Q2 net loss narrows to USD 1.8 million; revenue slips to USD 0.3 million
E
EVGN• Second-quarter results
- Evogene posted a Q2 net loss of USD 1.8 million, narrowing from USD 4.7 million a year earlier.
- Q2 revenue slipped to USD 0.3 million from USD 0.5 million, mainly on the conclusion of AgPlenus’ Bayer agreement in May 2026.
- Cash and cash equivalents totaled USD 9.3 million at June 30, with Q2 cash usage of about USD 2.1 million.
- Full-year 2026 cash usage forecast at USD 8.5 million-USD 9.5 million, down from about USD 14.4 million in 2025.
- Operationally, six active drug collaborations; virtual chemical space expanded to about 110 billion molecules, supported by AI Agents and new models.
GNPX
•
